35 terminated. 35 Phase 1, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Terminated 35 |
| Phase 2 | 18 | Terminated 18 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus YTS109 cell injection - Lupus Nephritis (LN), Immune Thrombocytopenia (ITP) | Phase 1 | Terminated | China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 | 2025-04-16 | 2026-10-14 |
| BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B BE-101 - Hemophilia B, Hemophilia B, Moderately Severe or Severe | Phase 1 / Phase 2 | Terminated | Be Biopharma | 5 | 2024-12-04 | 2026-06-15 |
| Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B verbrinacogene setparvovec - Hemophilia B | Phase 1 / Phase 2 | Terminated | Spur Therapeutics | 6 | 2021-12-06 | 2026-07-31 |
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device Marstacimab PFP, Marstacimab PFS - Healthy Volunteers | Phase 1 | Terminated | Pfizer | 22 | 2021-03-30 | 2022-07-11 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A SIG-001 - Hemophilia A | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 3 | 2020-09-28 | 2024-09-04 |
| A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects SHP648 - Hemophilia B | Phase 1 / Phase 2 | Terminated | Baxalta now part of Shire | 2 | 2020-05-13 | 2022-05-19 |
| Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A OCTA101 - Severe Hemophilia A | Phase 1 / Phase 2 | Terminated | Octapharma | 36 | 2019-07-03 | 2026-10-15 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients Biological: M254, Placebo, Intravenous immunoglobulin (IVIg) - Immune Thrombocytopenic Purpura (ITP) | Phase 1 / Phase 2 | Terminated | Momenta Pharmaceuticals, Inc. | 50 | 2018-12-21 | 2025-05-28 |
| A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy FLT180a - Hemophilia B | Phase 1 / Phase 2 | Terminated | Spur Therapeutics | 10 | 2018-07-10 | 2023-07-20 |
| Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 Valoctocogene Roxaparvovec - Hemophilia A, Gene Therapy | Phase 1 / Phase 2 | Terminated | BioMarin Pharmaceutical | 3 | 2018-04-24 | 2025-08-22 |
| A Factor IX Gene Therapy Study (FIX-GT) FLT180a - Hemophilia B | Phase 1 / Phase 2 | Terminated | University College, London | 10 | 2017-12-05 | 2022-12-02 |
| A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant - Healthy, Primary Immune Thrombocytopenia | Phase 1 | Terminated | Pfizer | 58 | 2017-07-17 | 2024-07-05 |
| Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B SB-FIX - Hemophilia B | Phase 1 | Terminated | Sangamo Therapeutics | 1 | 2016-11-15 | 2024-07-19 |
| Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B DTX101 - Hemophilia B | Phase 1 / Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 6 | 2015-12-16 | 2018-11-14 |
| PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP PRTX-100 - Immune Thrombocytopenia | Phase 1 / Phase 2 | Terminated | Protalex, Inc. | 15 | 2015-11-01 | 2019-03-25 |
| PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP PRTX-100 - Immune Thrombocytopenia | Phase 1 / Phase 2 | Terminated | Protalex, Inc. | 13 | 2015-09-01 | 2019-07-05 |
| Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin Warfarin adjustment using the Fearon algorithm, Warfarin adjustment using standard dosing - Hypoprothrombinemia | Phase 1 / Phase 2 | Terminated | McMaster University | 42 | 2014-11-01 | 2018-04-06 |
Showing 20 of 35. Sign in to see all of them.
Hemophilia B (10) · Purpura, Thrombocytopenic, Idiopathic (9) · Hemophilia A (8) · Polycythemia Vera (6) · Primary Myelofibrosis (6) · Thrombocythemia, Essential (6) · Myeloproliferative Disorders (5) · Hematologic Diseases (3) · Leukemia, Myeloid, Acute (3) · Leukemia, Myelomonocytic, Chronic (3) · Blood Coagulation Disorders, Inherited (2) · Burkitt Lymphoma (2) · Coagulation Protein Disorders (2) · Genetic Diseases, Inborn (2)
Hemic and Lymphatic Diseases (35) · Hematologic Diseases (32) · Hemorrhagic Disorders (32) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Blood Coagulation Disorders, Inherited (17) · Blood Platelet Disorders (17) · Genetic Diseases, Inborn (17) · Coagulation Protein Disorders (16) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Immune System Diseases (11) · Genetic Diseases, X-Linked (10) · Cytopenia (9) · Hemorrhage (9)
Staphylococcal Protein A (3) · ARC19499 (1) · Acetylcysteine (1) · Arsenic Trioxide (1) · Ascorbic Acid (1) · BI 655064 (1) · Bevacizumab (1) · CPX-351 (1) · Cytarabine (1) · Daunorubicin (1) · Erythromycin (1) · GMA-161 (1) · Immunoglobulins, Intravenous (1) · Injections (1) · Injections, Intra-Articular (1)
Protalex, Inc. (3) · Baxalta now part of Shire (2) · Pfizer (2) · Spur Therapeutics (2) · Alliance for Clinical Trials in Oncology (1) · Astex Pharmaceuticals, Inc. (1) · Avigen (1) · Be Biopharma (1) · BioMarin Pharmaceutical (1) · Boehringer Ingelheim (1) · Catalyst Biosciences (1) · China Immunotech (Beijing) Biotechnology Co., Ltd. (1) · Eli Lilly and Company (1) · Exelixis (1) · Genzyme, a Sanofi Company (1)
United States (23) · United Kingdom (11) · Spain (4) · Belgium (3) · Italy (3) · Australia (2) · Bulgaria (2) · Canada (2) · France (2) · New Zealand (2) · Taiwan (2) · Austria (1) · China (1) · Germany (1) · Hungary (1)
Edward Bernton, MD (1) · Eunice Wang, MD (1) · Momenta General Queries (1) · Peter H Chang, D.O. (1) · Pratima Chowdary (1) · Roger Strair, MD, PhD (1) · Sam Schulman, MD, PhD (1)
PMID 35857660, PMID 23829485, PMID 27515248, PMID 36299240, PMID 40197980, PMID 42698050
2018 (3), 2014 (1), 2017 (1), P30CA072720 (1), U10CA031946 (1)